The Long Island Parkinson's Disease Center

描述(申请人提供)：帕金森病(PD)是一种常见的退行性神经系统疾病，影响大约100万美国人。在过去的十年里，帕金森病的治疗和管理的进步越来越需要普通神经科医生向运动障碍专家寻求建议，以优化帕金森病患者的护理。随着对帕金森病病理生理学认识的不断深入，延缓帕金森病病程的新策略不断涌现。随着这些疗法已经开始进入临床试验，患者已经并可能继续主要通过PD中心获得这些试验。我们在纽约州长岛或附近组建了一个PD专家网络，他们结合了PD管理方面的实践经验、广泛的临床试验经验以及与开发用于评估PD治疗的成像方法相关的临床研究成果。凭借这一PD临床试验和研究经验以及非常广泛的人群基础，我们处于独特的地位，可以实现以下具体目标：1)成功参与计划中的大规模PD简单神经保护临床试验。在北岸大学医院(NSUH)，我们拥有成功完成PD临床试验和临床研究招募的长期记录；以及2)为计划中的临床试验提供有关潜在神经成像标记物的专业知识。国立国立卫生研究院的功能成像实验室一直专注于帕金森病治疗的评估。Feigin博士和Eidelberg博士目前由NINDS资助，研究与帕金森病潜在神经保护剂评估直接相关的问题，因此具有独特的视角，可能有助于未来临床试验的规划。为了支持我们能够成功实现这些特定目标的论点，这项申请将集中在五个方面：1)我们收集地区的人口统计数据；2)描述我们目前的PD患者群体和我们的多学科PD中心；3)计划进一步为计划中的临床试验招募人员；4)我们中心人员在通过多中心财团和独立进行临床试验的方方面面的经验；以及5)我们对PD治疗的影像研究的简要描述。

DESCRIPTION (provided by applicant): Parkinson's disease (PD) is a common degenerative neurological disease, affecting approximately 1 million Americans. Advances in the treatment and management of PD over the past ten years have increasingly required general neurologists to seek advice from Movement Disorders specialists in order to optimize PD patient care. With advances in the understanding of the pathophysiology PD, new strategies for slowing the course of PD are emerging. As these therapies have begun to move to clinical trials, patient access to these trials has been and will likely continue to be primarily through PD centers. We have assembled a network of PD specialists in or near Long Island, NY with a combination of practical experience in the management of PD, extensive clinical trial experience, and clinical research excellence related to the development of imaging methods for assessing therapies for PD. With this combination of PD clinical trial and research experience and a very broad population base, we are uniquely positioned to achieve the following Specific Aims: 1) To participate successfully in the planned large-scale simple neuroprotective clinical trial for PD. At North Shore University Hospital (NSUH) we have a long track record of successful completion of clinical trials for PD and of recruitment for clinical research; and 2) To provide expertise regarding potential neuroimaging markers for the planned clinical trial. The functional imaging laboratory at NSUH has focused on the assessment of therapies for PD. Drs. Feigin and Eidelberg are currently funded by NINDS to study issues directly related to the assessment of potential neuroprotective agents for PD and therefore have a unique perspective that may be of benefit for the planning of the future clinical trial. To support our contention that we can successfully achieve these Specific Aims, this application will focus on five areas: 1) The demographics of our catchment area; 2) A description of our current PD patient population and our multidisciplinary PD center; 3) Plans to further enhance recruitment for the planned clinical trial; 4) The experience of our center personnel with all aspects of clinical trial conduct both through multicenter consortiums and independently; and 5) A brief description of our imaging studies of therapies for PD.